BioStock: Elicera's potential in cancer therapy published in Nature Communications

Elicera Therapeutics uses CAR T-cells as a basis for two of its four cancer immunotherapy programmes. The ELC-401 programme addresses challenges in treating solid tumours, glioblastoma specifically, where the microenvironment is extremely hostile to immunotherapies. Through a recent article published in Nature Communications, Elicera sheds light on the potential of the CAR T construct used within ELC-401.

Read the article at biostock.se:

Elicera's potential in cancer therapy published in Nature Communications - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/